相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
Xuewei Cheng et al.
ACTA PHARMACEUTICA SINICA B (2017)
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
John O. Miners et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3
Rongrong Jiang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases
Nan Zhang et al.
SCIENTIFIC REPORTS (2015)
Renal Tubular Secretion of Tanshinol: Molecular Mechanisms, Impact on Its Systemic Exposure, and Propensity for Dose-Related Nephrotoxicity and for Renal Herb-Drug Interactions
Weiwei Jia et al.
DRUG METABOLISM AND DISPOSITION (2015)
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective
Roelof W. F. van Leeuwen et al.
LANCET ONCOLOGY (2014)
Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases
Limei Ai et al.
XENOBIOTICA (2014)
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Rashmi R. Shah et al.
DRUG SAFETY (2013)
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
Colin F. Spraggs et al.
PHARMACOGENOMICS (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Combinatorial Metabolism Notably Affects Human Systemic Exposure to Ginsenosides from Orally Administered Extract of Panax notoginseng Roots (Sanqi)
Zheyi Hu et al.
DRUG METABOLISM AND DISPOSITION (2013)
Intestinal Absorption and Presystemic Elimination of Various Chemical Constituents Present in GBE50 Extract, a Standardized Extract of Ginkgo biloba Leaves
Li Li et al.
CURRENT DRUG METABOLISM (2012)
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Suneet Shukla et al.
DRUG RESISTANCE UPDATES (2012)
Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases
Yong Liu et al.
DRUG METABOLISM AND DISPOSITION (2010)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Determination of Human Serum alpha(1)-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Ferenc Zsila et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Transport and metabolism of flavonoids from Chinese herbal remedy Xiaochaihu-tang across human intestinal Caco-2 cell monolayers
Jie-Yu Dai et al.
ACTA PHARMACOLOGICA SINICA (2008)
Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study
Regina I. Jakacki et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Population pharmacokinetics of imatinib and the role of α1-acid glycoprotein
N. Widmer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells:: in vitro and in cancer patients
Jing Li et al.
INVESTIGATIONAL NEW DRUGS (2006)
The human intestinal cytochrome P450 pie
MF Paine et al.
DRUG METABOLISM AND DISPOSITION (2006)
Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma
B Guo et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2006)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The small intestine as a xenobiotic-metabolizing organ
LS Kaminsky et al.
DRUG METABOLISM AND DISPOSITION (2003)
Confidence interval criteria for assessment of dose proportionality
BP Smith et al.
PHARMACEUTICAL RESEARCH (2000)
Drug-like properties and the causes of poor solubility and poor permeability
CA Lipinski
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2000)
分享论文
